RT
VRTX icon

Robert Torray’s Vertex Pharmaceuticals VRTX Stock Holding History

Robert Torray’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.56M Sell
15,215
-171
-1% -$75.8K 1.02% 32
2026
Q1 		$6.87M Sell
15,386
-80
-0.5% -$37.3K 1.01% 30
2025
Q4 		$7.01M Sell
15,466
-789
-5% -$340K 1% 31
2025
Q3 		$6.37M Sell
16,255
-624
-4% -$261K 0.86% 40
2025
Q2 		$7.51M Buy
16,879
+1,158
+7% +$534K 1.09% 33
2025
Q1 		$7.62M Sell
15,721
-287
-2% -$134K 1.14% 34
2024
Q4 		$6.45M Buy
16,008
+257
+2% +$119K 0.92% 40
2024
Q3 		$7.33M Buy
15,751
+1,813
+13% +$871K 1.03% 33
2024
Q2 		$6.53M Buy
13,938
+39
+0.3% +$16.9K 0.98% 38
2024
Q1 		$5.81M Sell
13,899
-169
-1% -$71.4K 0.87% 40
2023
Q4 		$5.72M Buy
+14,068
New +$5.2M 0.93% 40
2014
Q2 		– Sell
-76,397
Closed -$5.4M – 94
2014
Q1 		$5.4M Buy
76,397
+22,117
+41% +$1.75M 0.92% 54
2013
Q4 		$4.03M Buy
54,280
+8,310
+18% +$579K 0.84% 47
2013
Q3 		$3.48M Buy
45,970
+598
+1% +$47.6K 0.75% 49
2013
Q2 		$3.63M Buy
+45,372
New +$3.34M 0.79% 46

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Robert Torray's VRTX Position: Q2 2026 in Review

Robert Torray reduced its Vertex Pharmaceuticals (VRTX) stake by 1.1% in Q2 2026, selling an estimated $75.8K and leaving 15,215 shares worth $7.56M. The position accounts for 1.02% of the portfolio, ranked #32.

Robert Torray first reported a position in VRTX in Q2 2013 and has held it in 15 quarters since. The position peaked at $7.62M in Q1 2025. 1,747 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Robert Torray held 15,215 shares of Vertex Pharmaceuticals worth $7.56M as of Q2 2026.
  • Robert Torray sold 171 Vertex Pharmaceuticals shares in Q2 2026, an estimated $75.8K.
  • Vertex Pharmaceuticals made up 1.02% of Robert Torray's portfolio in Q2 2026, its #32 holding.
  • Robert Torray first reported a position in Vertex Pharmaceuticals in Q2 2013 and has held it in 15 quarters since.
  • Robert Torray's Vertex Pharmaceuticals position peaked at $7.62M in Q1 2025.
  • 1,747 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Torray Investment Partners's 13F filing for Q2 2026, filed 30 Jul 2026.